CuraTech nominated Finalist in the Diabetes Australia Grand Innovation Challenge 2026

22 June 2026

We are incredibly proud that CuraTech and Surgical BioFix - with REVITA - have been selected as one of just 10 finalists in the Diabetes Australia Grand Innovation Challenge 2026!

Around 50,000 Australians experience a diabetic foot ulcer each year, often with a devastating impact on their quality of life and a significant burden on our healthcare system. When standard wound care isn’t enough, clinicians and patients urgently need another option.

𝗥𝗘𝗩𝗜𝗧𝗔 is an innovative, Australian-produced placental membrane allograft designed to support healing when difficult-to-heal wounds have stalled. Early clinical results are encouraging, and the Grand Innovation Challenge could help us build the robust Australian clinical and health-economic evidence needed to bring this innovation to more patients.

Because better healing could mean fewer infections, fewer hospital stays, fewer amputations – and a profound difference for patients and their families.

We are thrilled to be among the finalists and look forward to presenting 𝗥𝗘𝗩𝗜𝗧𝗔 at the Grand Final at the Diabetes Community Day at the IDF-WPR Congress 2026!

Find out more about REVITA here.